Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12271275 | 0.89 | GPR119 (0.60) | GPR119CYP2C9BRD4PTGS2PTGS1 | |
| SCHEMBL10105824 | 0.87 | GPR119 (0.48) | GPR119CYP2C9BRD4PTGS2PTGS1 | |
| SCHEMBL10120668 | 0.86 | GPR119 (0.46) | GPR119CYP2C9PTGS2PTGS1 | |
| SCHEMBL10134280 | 0.84 | PTGS2 (0.45) | GPR119CYP2C9BRD4PTGS2PTGS1 | |
| SCHEMBL10116422 | 0.82 | GPR119 (0.50) | GPR119CYP2C9BRD4PTGS2PTGS1 | |
| SCHEMBL10105802 | 0.80 | GPR119 (0.54) | GPR119CYP2C9 | |
| SCHEMBL10116292 | 0.79 | GPR119 (0.55) | GPR119CYP2C9BRD4PTGS2PTGS1 | |
| SCHEMBL15381350 | 0.78 | GPR119 (0.53) | GPR119CYP2C9BRD4PTGS2PTGS1 | |
| SCHEMBL10116389 | 0.77 | GPR119 (0.46) | GPR119CYP2C9BRD4PTGS2PTGS1 | |
| SCHEMBL10121050 | 0.77 | GPR119 (0.46) | GPR119CYP2C9PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | GPR119 1/4885CYP2C9 999/4885BRD4 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.